Raptor Pharmaceuticals

Horizon Pharma to acquire Raptor Pharmaceutical

Wednesday, September 14, 2016

Horizon Pharma and Raptor Pharmaceutical have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million. The transaction is expected to close in the fourth quarter of 2016.

[Read More]